Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 3/20 | 0.72 |
| ▸ | FEN1 | P39748 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987169 | 0.89 | ERCC5 (0.74) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL28066677 | 0.84 | FEN1 (1.00) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL8180621 | 0.84 | ERCC5 (0.68) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL29033943 | 0.83 | ERCC5 (0.67) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL30802824 | 0.82 | ERCC5 (0.65) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL10576213 | 0.82 | ERCC5 (0.59) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL2519308 | 0.82 | ERCC5 (0.65) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL2492019 | 0.82 | ERCC5 (0.65) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL15979733 | 0.80 | CES2 (0.62) | ERCC5FEN1POLBALDH1A1CES2 | |
| SCHEMBL31582272 | 0.80 | MEN1 (0.69) | ERCC5FEN1POLBALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106995394-B | The preparation method of β -one sulfones | 齐齐哈尔大学 | 2018-09-07 | — | — | CN | claimed |
| CN-107876092-A | The high stability titanium catalyst of ester exchange carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2018-04-06 | — | — | CN | claimed |
| CN-107417719-A | A kind of titanium chelate catalyst for being used for carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2017-12-01 | — | — | CN | claimed |
| CN-106995394-A | The preparation method of β ketone sulfones | 齐齐哈尔大学 | 2017-08-01 | — | — | CN | claimed |
| EP-3268372-B9 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-10-29 | — | — | US | disclosed |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3268372-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | 4SC AG (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-3268374-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2019-09-25 | — | — | EP | disclosed |
| WO-2004094421-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2004-01-15 | — | — | US | disclosed |
| WO-2003084937-A2 | PYRIMIDINEDIONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
| EP-0112617-B1 | PROCESS FOR THE EXTRACTION OF METAL VALUES AND NOVEL METAL EXTRACTANTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-12-30 | — | — | EP | disclosed |
| US-4581220-A | CURED RESIDUE OF ZIRCONIUM SOLUTION | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1986-04-08 | — | — | US | disclosed |
| US-4576815-A | Process for the extraction of metal values and novel metal extractants | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1986-03-18 | — | — | US | disclosed |
| EP-0112617-A1 | Process for the extraction of metal values and novel metal extractants | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-04 | — | — | EP | disclosed |
| US-4336389-A | 2-Substituted-4-aryl-5-thiazolecarboxylic acids and their derivatives as safening agents | MONSANTO COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | KCNA3, KCNN3, KCNH3 | ERCC5 4479/4885FEN1 4796/4885POLB 4798/4885 |
| US-20040009975-A1 | Novel pyrimidinedione derivatives | TYMS, DPYD, TYMP | ERCC5 852/4885FEN1 1157/4885POLB 204/4885 |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNA3, KCNN3, KCNK3 | ERCC5 4661/4885FEN1 4853/4885POLB 4471/4885 |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | ERCC5 4661/4885FEN1 4853/4885POLB 4471/4885 |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | ERCC5 4661/4885FEN1 4853/4885POLB 4471/4885 |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNN3, KCNN2, KCNA3 | ERCC5 4193/4885FEN1 4692/4885POLB 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.